CME

Faculty: Barbara O'Brien, MD

Faculty: Nadia Harbeck, MD, PhD

What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

Faculty: Barbara O'Brien, MD

Faculty: Nadia Harbeck, MD, PhD

What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

Faculty: Benjamin Levy, MD

Faculty: Melin Khandekar, MD, PhD

What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

Faculty: Benjamin Levy, MD

Faculty: Melin Khandekar, MD, PhD

What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

Faculty: Benjamin Levy, MD

What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will evaluate emerging evidence on the intracranial activity of systemic therapies and consider how tumor biology, symptom burden, and prior treatment inform therapy selection. This activity also highlights multidisciplinary collaboration among medical oncology, radiation oncology, and neuro-oncology to support coordinated care including management of CNS-related toxicities and optimize outcomes for patients with brain metastases from breast or lung cancer.

Host: Sandhya Khurana, MD, FCCP

Guest: Syed Shahzad Mustafa, MD

Guest: Ashley Wilk, DO, DipABLM

Part of the educational program Bridging Specialties®: Timely Diagnosis and Treatment for Refractory Chronic Cough, this activity examines the diagnostic challenges associated with refractory chronic cough (RCC) and the importance of coordinated, guideline-directed evaluation across specialties. RCC is frequently characterized by prolonged diagnostic delays, repeated empiric treatments, and fragmented care across specialties. Many patients experience months of persistent symptoms before a structured evaluation is implemented. This activity highlights practical strategies for applying a CHEST guideline-directed diagnostic pathway to improve efficiency, reduce unnecessary repetition, and support timely multidisciplinary coordination. Clinicians will gain tools to streamline evaluation and reduce patient burden.

Host: Carole Bitar, MD, FAAD

Guest: Matthew P. Giannetti, MD

Guest: Benjamin Ungar, MD

On-demand webcast featuring best practices for assessing and diagnosing patients with systemic mastocytosis, the latest data on new and emerging therapies, and strategies for providing patient-centered care.

Faculty: Mukul Sharma, MD, MSc, FRCPC

Faculty: Ashkan Shoamanesh, MD, MSc, FRCPC

Preventing stroke is critical, but for many patients, the fear of uncontrolled bleeding stands in the way of anticoagulation. What if we didn’t have to choose? Explore the emerging role of Factor XI/XIa inhibition and how it may redefine the balance between thrombosis and hemostasis. You’ll break down the science behind FXI, review key clinical trial data, and examine where these therapies may fit in secondary stroke prevention. Through real-world scenarios, discover how FXI inhibitors could help address residual stroke risk without the same bleeding concerns that limit current options.

Faculty: Carol Wysham, MD

Faculty: Samuel Seidu, MD, FRCP(Edin), FRCGP

Recently, an international panel of experts developed objective practical recommendations on how continuous ketone monitoring could improve diabetes care. Even more recently, new data was presented on the prevalence, risk, burden, and management of DKA. Join worldwide experts as they discuss the practical application of all of these advances into your current practice.

Faculty: David T. Rubin, MD

Faculty: Ugonna Iroku, MD, MHS

This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the pathophysiology of IBD and the immune mechanisms that contribute to chronic intestinal inflammation. Experts also discuss how various therapies interact with these pathways. The program concludes with practical insights on applying a mechanistic understanding of IBD to treatment strategy, disease monitoring, and management decisions in community gastroenterology practice.